Table 3

Treatment outcomes following induction chemotherapy of 595 adult patients with previously untreated AML, by treatment group

GroupPatientsCRCR or CriResistant diseaseOS at 5 yearsRFS at 5 years
%95% CI%95% CI%95% CI%95% CI%95% CI
DA+GO 295 69 63-74 76 69-79 15 12-20 46 40-52 43 36-50 
DA 300 70 64-75 74 69-79 20 16-25 50 44-56 42 35-49 
P*  .59 .36 .065 .85 .40 
GroupPatientsCRCR or CriResistant diseaseOS at 5 yearsRFS at 5 years
%95% CI%95% CI%95% CI%95% CI%95% CI
DA+GO 295 69 63-74 76 69-79 15 12-20 46 40-52 43 36-50 
DA 300 70 64-75 74 69-79 20 16-25 50 44-56 42 35-49 
P*  .59 .36 .065 .85 .40 
*

One-sided P value for superior outcome (higher CR rate, lower RD, HR<1) in DA+GO group, based on Fisher’s exact test (CR, RD) or logrank test (OS, RFS).

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal